Prophylactic inferior vena cava filters in trauma patients at high risk: Follow-up examination and risk/benefit assessment  by Langan, Eugene M. et al.
484
A thrombotic state develops in trauma patients
to physiologically assist in limiting blood loss.1,2 In
most surgical patients, the optimal method of
venous thromboembolism prophylaxis is subclinical
anticoagulation therapy and sequential compression
devices. These treatment options have not been
proven to be as beneficial in the critically injured
trauma patient.3-5 In addition to the other risk fac-
tors, associated with some traumatic injuries, of pro-
Prophylactic inferior vena cava filters in
trauma patients at high risk: Follow-up
examination and risk/benefit assessment
Eugene M. Langan III, MD, Richard S. Miller, MD, William J. Casey III,
MD, Christopher G. Carsten III, MD, Robin M. Graham, MS, and Spence M.
Taylor, MD, Greenville, SC
Purpose: The efficacy of prophylactic inferior vena cava filters in selected trauma patients
at high risk has come into question in relation to risk/benefit assessment. To evaluate
the usefulness of prophylactic inferior vena cava filters, we reviewed our experience and
overall complication rate.
Methods: From February 1991 to April 1998, the trauma registry identified 7333 admis-
sions. One hundred eighty-seven prophylactic inferior vena cava filters were inserted. After
the exclusion of 27 trauma-related deaths (none caused by thromboembolism), 160 patients
were eligible for the study. The eligible patients were contacted and asked to complete a sur-
vey and return for a follow-up examination to include physical examination, Doppler scan
study, vena cava duplex scanning, and fluoroscopic examination. The patients’ hospital
charts were reviewed in detail. The indications for prophylactic inferior vena cava filter
insertion included prolonged immobilization with multiple injuries, closed head injury,
pelvic fracture, spine fracture, multiple long bone fracture, and attending discretion.
Results: Of the 160 eligible patients, 127 were men, the mean age was 40.3 years, and the
mean injury severity score was 26.1. The mean day of insertion was hospital day 6.
Seventy-five patients (47%) returned for evaluation, with a mean follow-up period of 19.4
months after implantation (range, 7 to 60 months). On survey, patients had leg swelling
(n = 27), lower extremity numbness (n = 14), shortness of breath (n = 9), chest pain (n
= 7), and skin changes (n = 4). All the survey symptoms appeared to be attributable to
patient injuries and not related to prophylactic inferior vena cava filter. Physical exami-
nation results revealed edema (n = 12) and skin changes (n = 2). Ten Doppler scan stud-
ies had results that were suggestive of venous insufficiency, nine of which had histories of
deep vein thrombosis. With duplex scanning, 93% (70 of 75) of the vena cavas were visu-
alized, and all were patent. Only 52% (39 of 75) of the prophylactic inferior vena cava fil-
ters were visualized with duplex scanning. All the prophylactic inferior vena cava filters
were visualized with fluoroscopy, with no evidence of filter migration. Of the total 187
patients, 24 (12.8%) had deep vein thrombosis develop after prophylactic inferior vena
cava filter insertion, including 10 of 75 (13.3%) in the follow-up group, and one patient
had a nonfatal pulmonary embolism despite filter placement. Filter insertion complica-
tions occurred in 1.6% (three of 187) of patients and included one groin hematoma, one
arteriovenous fistula, and one misplacement in the common iliac vein.
Conclusion: This study’s results show that prophylactic inferior vena cava filters can be
placed safely with low morbidity and no attributable long-term disabilities. In this
patient population with a high risk of pulmonary embolism, prophylactic inferior vena
cava filters offered a 99.5% protection rate, with only one of 187 patients having a non-
fatal pulmonary embolism. (J Vasc Surg 1999;30:484-90.)
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longed immobilization and the inability or con-
traindication to anticoagulation therapy, trauma
patients are at an increased risk of deep vein throm-
bosis (DVT) and pulmonary embolism (PE).3,4 In
an attempt to prevent PE and its catastrophic seque-
lae on severely injured trauma patients and with the
advent of percutaneous, 12F Greenfield vena caval
filters (Medi-tech, Boston Scientific Corporation,
Watertown, Mass), many trauma centers advocate
the routine use of prophylactic inferior vena cava fil-
ters (PIVCF) in selected trauma patients at high
risk.7-17 With these facts accepted, the efficacy of
PIVCFs in relation to risk/benefit assessment in
trauma patients at high risk comes into question. To
evaluate the usefulness of PIVCFs and the short-
term and long-term complications, we reviewed our
experience at the Greenville Hospital System’s level
I trauma center and the overall complication rate.
METHODS
Between February 1991 and April 1998, 7333
patients were admitted and enrolled in the Greenville
Hospital System Trauma Center registry. Of these,
187 patients (2.6%) underwent PIVCF insertion.
The patients had a combination of injuries included
in the following categories: (1) closed head injury
with prolonged immobilization, (2) pelvic fracture
with impending surgery, (3) spine fracture with neu-
rologic deficit, (4) multiple long bone fractures, (5)
multiple injuries, and (6) trauma surgeon discretion.
All the patients who underwent PIVCF insertion
were expected to survive. The patients in each cate-
gory were anticipated to have prolonged immobiliza-
tion or a contraindication to anticoagulation therapy.
The PIVCF insertion categories were on the basis of
various trauma protocols.2,4-14 When a contraindica-
tion did not exist, all the patients underwent the con-
comitant optimal DVT prophylactic therapy as well,
including subcutaneous heparin therapy or sequential
compression devices.
All the PIVCFs were inserted percutaneously by
either vascular surgeons in the operating room or in
an intensive care unit procedure room or by inter-
ventional radiologists in the radiology suite. Either
the titanium or stainless steel Greenfield vena cava
filter was used, depending on the date of insertion.
The right femoral vein was used preferentially for
insertion because of the inability of early clearance of
neck injury, ventilatory support, or ease of access. If
the right femoral vein was unavailable, either the
right internal jugular vein or the left femoral vein
was used for the PIVCF insertion. Radiologic imag-
ing was used for all the PIVCFs inserted. An inferi-
or venacavogram was obtained to visualize the renal
veins, the size of the inferior vena cava (IVC), the
presence of venous anomalies, or the presence of
IVC thrombus. A DVT related to PIVCF insertion
was defined as occurring within 72 hours of filter
insertion and was confirmed with venous duplex
scanning results.
The outcomes data were obtained with chart
review. All the eligible patients were contacted and
asked to complete a questionnaire survey and to
return for follow-up physical examination. Questions
were asked about lower extremity swelling, shortness
of breath, chest pain, lower extremity skin changes,
and numbness. The physical examination included a
hand-held, continuous-wave, Doppler scan study to
assess for lower extremity venous augmentation and
insufficiency. The Doppler scan study was performed
by an attending trauma surgeon or a surgical resident.
An abdominal duplex scan examination (Acuson 128
XP, Acuson, Mountain View, Calif), performed by an
experienced registered vascular technologist, checked
for inferior vena cava patency and attempted to visu-
alize the PIVCF. A fluoroscopic study was performed
to radiologically visualize the PIVCF and to monitor
for possible filter migration. This procedure was per-
formed by an attending vascular surgeon. The differ-
ences in proportions were analyzed with c 2 test.
RESULTS
The indications for PIVCF insertion in the 187
patients are listed in Table I. There were three PIVCF
insertion complications for a complication rate of
1.6% (three of 187). The following complications
were included: a patient with a PIVCF improperly
placed in the right common iliac vein, which resulted
in a PE during left acetabular reconstruction; a
femoral arterial venous fistula found 1 month after
discharge, which underwent uneventful surgical
repair; and a groin hematoma after PIVCF insertion,
which was observed and treated without transfusion.
Table I. Categories of injuries and indications for
prophylactic inferior vena cava filter insertion
Category No. of patients
Closed head injury with prolonged 27 (14.4%)
immobilization
Pelvic fracture with impending surgery 25 (13.4%)
Spine fracture with neurologic deficit 25 (13.4%)
Multiple long bone fracture 11 (5.9%)
Multiple injuries 96 (51.3%)
Trauma surgeon discretion 3 (1.6%)
Total 187
In the study group, there were 27 trauma relat-
ed deaths (14.4%): 23 deaths occurred in the hospi-
tal, and four deaths occurred after discharge from
the trauma center. The cause of death was known for
each case and is listed in Table II. No death appeared
to be related to thromboembolism. The two respira-
tory deaths occurred in patients with quadriplegia
whose elective extubation failed and who refused
reintubation.
Of the 7333 admissions to the trauma center,
447 deaths (6.1%) occurred. The mortality rate was
statistically higher in the study group (14.4% vs
6.1%; P = .001).
Of the 160 surviving patients who were eligible
for the follow-up examination study group, 127
were men, the mean age was 40.3 years, and the
injury severity score was 26.1 (range, 4 to 75).
Seventy-five of the 160 eligible patients answered
questionnaire surveys and returned for follow-up
examination. The mean follow-up period was 19.4
months (range, 3 to 57 months).
On review of the questionnaire survey, 27
patients (36%) had leg swelling—seven unilateral
and 20 bilateral. Nine patients (12%) had shortness
of breath, four (5.3%) without a pretrauma history
of chronic obstructive pulmonary disease. Seven
patients (9.3%) had some chest pain or discomfort.
Four patients (5.3%) had lower extremity skin
changes, one with ulcers. All symptoms appeared to
be attributable to patient injuries and not related to
the PIVCF.
The physical examination results revealed mild
edema in 12 patients (all with pelvic fractures or lower
extremity injuries). Two had scaling skin changes,
consistent with dry skin. Ten (13.3%) continuous
wave Doppler scan studies had results that were sug-
gestive of venous insufficiency, nine with a previous
history of DVT. No patient had abnormal arterial
examination results. There was a minimal correlation
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between the questionnaire survey results and the
physical examination or Doppler scan study results.
The duplex scan examination results visualized 70
IVCs (93%), and all were patent. Five IVCs were not
visualized as the result of bowel gas. Only 39 PIVCFs
(52%) were seen with duplex scanning. One patient in
the study group had a suprarenal PIVCF placed for
thrombus above the renal vein. The IVC thrombus
was found during routine preinsertion venacavogram.
On duplex scanning, one IVC was patent with thick-
ened walls, which suggested chronic changes below
the PIVCF. All the PIVCFs were visualized with fluo-
roscopy, with no evidence of filter migration.
Of the 187 patients, 24 (12.8%) had intrahospi-
tal DVT develop after PIVCF insertion, document-
ed with duplex scanning, which included 10 patients
(13.3%) in the follow-up group of 75 patients. One
patient had a nonfatal PE that was confirmed with
ventilation-perfusion scanning and spiral computed
tomographic scanning. Therefore, there was one
known clinical PE in 187 patients (0.5%) in whom
PIVCFs were used. All the DVTs occurred at least
72 hours after filter insertion.
The determination of an overall composite inci-
dence of DVT and PE on the trauma service registry
was reviewed from July 1, 1994, through May 1,
1998. The registry identified 3788 trauma admis-
sions. Of these admissions, 61 patients (1.6%) had a
DVT develop that was detected with venous duplex
scanning and five patients (0.13%) had a PE that was
diagnosed with ventilation-perfusion scanning or
spiral computed tomographic scanning. The inci-
dence rate of DVT was statistically greater in the
PIVCF group than in the overall trauma population
(12.8% vs 1.6%; P = .001). The PE rates in the two
populations were found to be statistically similar
(0.5% vs 0.13%; P = .166).
DISCUSSION
With the technical advances in the Greenfield
vena cava filter design and a smaller percutaneous
carrier system (12F), insertion and placement have
become safer and easier. This has allowed possible
expansion of the clinical indications for PIVCF.18
Prophylactic insertion of Greenfield vena cava filters
in trauma patients who are at high risk has been pre-
viously reported and is supported by many trauma
surgeons.7-17 The literature, on the basis of autopsy
and clinical studies, suggests a high incidence of
venous thromboembolism in trauma patients as
compared with the general surgical patient popula-
tion.19-22 Trauma surgeons cite the lack of evidence
of successful DVT prophylaxis with the standard
Table II. Causes of death
No. of deaths
In-hospital deaths
Multi-system organ failure 10
Closed head injury 7
Sepsis 3
Cardiac disease 1
Respiratory failure 2
Total 23
Deaths after discharge
Closed head injury 1
Cardiac disease 3
Total 4
treatment options of subcutaneous heparin therapy
and sequential compression devices,3-5 coupled with
a subset of trauma patients who are unable to under-
go anticoagulation therapy and are immobile for
prolonged periods of time, as justification for pro-
tection against PE with the PIVCF.
To support this approach, the following four
controversial questions about PIVCFs need to be
answered:
1. Which patients need PIVCFs?
2. Are PIVCFs as effective as other prophylactic
treatments in preventing PE?
3. Is PIVCF insertion safe?
4. What are the long-term effects of PIVCFs?
Our study did not attempt to answer the contro-
versial question regarding which patients need
PIVCFs. Until a randomized prospective study is
completed, we concede that the controversy over
appropriate patient selection will persist. Despite
this, we believe that the available literature strongly
supports the use of PIVCFs in certain high-risk
groups.2,7-17
The second question compares other prophylactic
treatments with PIVCFs in the prevention of PE.
Other studies cite that historical controls to document
a PE rate in trauma patients not protected with
PIVCFs of between 1% and 23%.7-10,12,14 Rogers et
al14 reported that 92% (23 of 25) of PEs occur in high-
risk trauma categories unprotected with PIVCFs. Our
study documented only one PE in 187 patients
(0.5%), which suggests outstanding PE protection.
This is more significant when we consider that the
high-risk group had a statistically greater DVT rate
(12.8% vs. 1.6%) than did the general trauma popula-
tion and that the PE rates were statistically similar
(0.5% vs 0.13%), which again suggests excellent PE
protection. The higher incidence rate of DVT in the
study group perhaps illustrates the hypercoagulable
nature of this patient subset and reiterates that PIVCF
insertion is for PE, not DVT prophylaxis. It should be
stressed that DVT prophylaxis should be continued
whenever possible, even though current prophylaxis
can be suboptimal in this high-risk patient population.
Hopefully, low–molecular weight heparin therapy or
new prophylactic methods will be developed that will
offer future DVT prevention. Until a proven better
method of DVT/PE protection is found, PIVCFs
should be strongly considered in this patient group.
The question of the safety of PIVCFs is addressed
in this respect. Our data show that PIVCFs can be
inserted with minimal early technical complications
(1.6%) and no insertion-site DVTs. There was not a
routine DVT surveillance in place for trauma patients
after PIVCF insertion. The patients underwent
venous duplex scan studies on the basis of symptoms.
Of the 24 post–PIVCF insertion DVTs, 13 were ipsi-
lateral and 11 were contralateral, which suggests no
relation to the PIVCF insertion site. Therefore, we
believe that in this high-risk, hypercoagulable patient
group, despite a mortality rate that is higher than
that of the overall trauma population (14.4% vs
6.1%), PIVCF insertion appears safe and can be jus-
tified for PE prophylaxis.
The final question inquires about the long-term
side effects of PIVCFs. Our follow-up examination
results revealed the subjective symptoms of lower
extremity edema or skin changes in 31 patients
(41.3%). However, physical examination results
revealed these findings in only 14 patients (18.7%)
and late Doppler scan findings of DVT were docu-
mented in 10 patients (13.3%). The examiners
believed that these problems were most likely the
result of DVT or the traumatic injury and its seque-
lae and not a direct consequence of the PIVCF itself.
No filter migration or IVC thrombosis occurred
during the mean follow-up period of 19.4 months.
These data suggest that IVC filters usually remain
innocuous and follow a benign course.
This study also shows that physical examination
alone is unreliable for the detection of chronic
venous changes and that a Doppler scan study in
trained hands can be precise in most patients (74 of
75). Duplex scan results can accurately visualize IVC
patency but are unacceptable in the monitoring of
filter migration, for which fluoroscopy was our best
imaging method.
Another concern surrounding the prophylactic
use of Greenfield vena cava filters is cost.23 Current
costs are estimated at approximately $5000 per filter
insertion.11,24 Although this is a high cost per life
saved, $5000 is a small sum relative to the overall
hospital costs involved with caring for this trauma
patient subset. Furthermore, attempts can be made
to reduce costs by using a “no charge” intensive care
unit procedure room or by placing the filter at the
bedside to avoid the expense of radiology charges.
Costs can also be reduced by coordinating PIVCF
insertion with other procedures in the operating
room or in the interventional suite when possible.
In conclusion, this experience suggests that
PIVCFs are effective in PE prophylaxis for trauma
patients who are at high risk and can be inserted and
placed with minimal short-term and long-term com-
plications in patients who are followed for a mean
period of 19.4 months. Although prospective stud-
ies are needed to definitively determine the appro-
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priate patients who are best suited for PIVCF, this
study supports their use in high-risk groups of trau-
ma patients for the prevention of PE.
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Dr Lazar J. Greenfield (Ann Arbor, Mich). I congrat-
ulate the authors on their efforts and commend the man-
uscript to your subsequent review.
Dr Langan and his associates have reported outcomes
for a group of 187 patients with multiple injuries who
received prophylactic filters during a 7-year period. Their
data were obtained from patient survey, physical examina-
tion, and clinical studies, and, as you saw, their outcomes
are excellent, with a 100% patency rate among those
patients with adequate studies and with only one pul-
monary embolic event after filter placement.
This study is important for several reasons. First, it
provides objective documentation of the low adverse event
rates related to prophylactic filter placement, which should
alleviate most of the concerns of those who fear placing
permanent devices in patients with a presumed time-limit-
ed risk of thromboembolism.
Second, the authors report a 13% incidence rate of
DVT in this group of patients, which means that 87% of
these 162 placements were ultimately unnecessary. This
points out the critical need to identify more accurately
those patients who are at highest risk of DVT because cur-
rent risk factors clearly lack specificity.
Third, the disparity between the survey results of
patient complaints and the clinical studies point out that
there are misperceptions that result when reports are based
on subjective data unsupported by objective evaluation. In
a recent consensus conference on vena caval filters, we have
recommended specific reporting standards for patient fol-
low-up that should improve the quality of publications.
I have four questions for the authors.
First, among the indications, what types of situations
were covered by the category of trauma surgeon discretion
and multiple injuries, and did any of them develop DVT?
DISCUSSION
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 3 Langan et al 489
Second, which patients were given pharmacologic
prophylaxis with heparin, and was there any difference in
the incidence of DVT?
Third, how were patients who developed DVT treat-
ed, and was there any correlation between the inability to
anticoagulate and long-term sequelae?
And, finally, in our series of trauma patients with pro-
phylactic filters, we observed a higher incidence of filter
occlusion by massive embolus. Half of them subsequently
lysed with reopening of the vena cava, and the question is,
can this explain your finding of bilateral lower extremity
edema in some patients, or did they in fact have bilateral
DVT initially?
I enjoyed the paper and appreciate the opportunity to
comment on these results.
Dr Eugene M. Langan III. Thank you, Dr Greenfield,
for your expertise and comments and questions.
First of all, the indications. There were three patients
in the trauma surgeon discretion category. Our trauma
surgeons, if they have a patient who will be immobile for
an extensive period of time, because of either being an
elderly patient or because of their trauma situation, then
they are liberal in their use of filters. Three of 187 is not a
large amount, but they believed that those three patients
required filters, and we corresponded by placing the filter.
As for the patients with multiple injuries, they fall into
the group in which all categories would be mixed, such as
the patient I showed you with the closed head injury and
the fractured injured groups.
As far as heparinization for DVT treatment, we rec-
ommend that all of our patients who have filters placed
still receive the benefit of DVT prophylaxis. We do not
view that the Greenfield filter is the catch-all and is a pre-
vention for DVT. We view this as PE prophylaxis, and
DVT therapy needs to continue whenever possible unless
the patient has a contraindication to either one of the ther-
apies.
As far as inferior vena caval occlusion, we did not find
any inferior vena caval occlusions when we scanned our
patients. Although we had five patients with bowel gas or
inability to stand or caval occlusion whose DVTs were
incredibly difficult for us to visualize, we do not think that
the caval occlusion occurred.
As for the patients who had the bilateral lower extrem-
ity swelling, interestingly enough, when they returned for
follow-up examination, there were very few of them who
actually had that on physical examination. Therefore, we
question whether they truly had it or whether they had
DVT that subsequently lysed.
Dr Roger T. Gregory (Norfolk, Va). I enjoyed your
paper primarily because we agree with your approach.
Trauma patients are very difficult to move to the operat-
ing room. We have a series in Norfolk now of more than
50 patients who were treated with a prophylactic IVC fil-
ter. All of these patients had bedside placement of their fil-
ter with duplex scan monitoring. Cost savings in this
patient group were more than $2000 per patient. No pul-
monary embolus was observed on follow-up examination.
I have two questions. First, have you considered bed-
side IVC filter placement with duplex scan–directed mon-
itoring techniques? Second, is this a patient group in
which a temporary IVC filter would be useful?
Thank you.
Dr Langan. Thank you for your questions. We have
considered using duplex ultrasound scanning for the
placement of these filters. We happen to be fortunate
enough in that we have a “no charge” intensive care unit
procedure room that we can use with our own fluoroscopy
that we run ourselves. This fluoroscopy avoids all possible
charges from radiology. And we also have intensive care
unit beds, which allow us to place the filters directly at the
bedside with this same fluoroscopy, which is portable,
which eliminates the need for that. And therefore we
viewed this as a better way to do this currently than with
duplex ultrasound scannning.
The second question was about removable filters. Yes,
in most of these patients, a removable filter would be an
adequate way to go. The question would be how long the
removable filter would be left in place.
Thank you.
Dr Gary M. Gross (Huntsville, Ala). In those patients
who developed deep vein thrombosis after filter insertion,
was thrombosis more common on the side of the femoral
vein cannulation? That would answer a criticism that is
sometimes raised of the femoral approach—that the vein
cannulation is a cause of venous thrombosis.
Secondly, you mentioned that you always visualize a
renal vein. I found that very difficult in the intensive care
unit with a C-arm. Do you really see the renal vein in
those cases or are you just estimating the location?
Lastly, in the occasional case in which the filter is
released too low with struts in the common iliac vein,
which does happen, what should be done? Should we
place a second filter above?
Dr Langan. Well, regarding your question on visual-
ization of the renal veins, we actually do see most of the
renal veins with the C-arm. We have the OEC C-arm that
we use, and we do see a flush. Obviously, you do not see
terrifically delineated renal veins all the time, but you do
see a flush.
As for the second filter. Yes, we believe a second filter
should be placed. We do place the filter, though, in the
proper location. We do not place it in the other iliac vein.
Dr Gregory. And the site of insertion?
Dr Langan. No, there was no difference, none what-
soever. 
Dr Mark L. Friedell (Orlando, Fla). That was my
question. Some studies have shown that the femoral vein
insertion site can lead to DVT, and is it possible that the
insertion caused the DVT in your patients who developed
it? And if so, should we be trying to put these filters in
through the internal jugular vein preferentially?
Dr Langan. Well, when we started putting in the filters
for the trauma service, we were preferentially trying to use
the internal jugular vein. But because of the fact that so
many of these would have necks that were not cleared,
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patients with difficult conditions with ventilatory support,
we went to the right femoral vein, which we found to be
actually easier, and we followed these up closely. There was
no difference in the DVT rate for either extremity.
Dr G. Patrick Clagett (Dallas, Tex). I am still con-
fused. Do you think the filter caused the DVT, or was this
just a higher risk patient population? It is reminiscent of
data from the French study that showed that filter place-
ment on long-term follow-up was associated with a high-
er incidence of DVT.
Dr Langan. We think that the DVT is unrelated to the
filter that we found.
Dr Kenneth E. McIntyre (Dallas, Tex). I was interest-
ed in the comparison between the standard trauma group
and the group who were considered “high risk.” I think
your results might be more accurate if you compared the
incidence of pulmonary embolism or DVT in trauma
patients with the same injury severity scores.
Your “high risk” group had an average injury severity
score of 26, but the injury severity score for the entire
trauma population is going to be much lower. Therefore,
the incidence of DVT or pulmonary embolism may actu-
ally be much higher than you might have anticipated
because trauma and stasis (brought on by bedrest) are
known risk factors even in less severely injured patients.
Dr Langan. That is an excellent suggestion. Thank you.
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